[Efficacy of different doses and timing of tranexamic acid in major orthopedic surgeries: a randomized trial].

Eficácia de diferentes doses e esquemas de administração de ácido tranexâmico em cirurgias ortopédicas de grande porte: estudo randomizado.

Journal

Brazilian journal of anesthesiology (Elsevier)
ISSN: 2352-2291
Titre abrégé: Braz J Anesthesiol
Pays: Brazil
ID NLM: 101624623

Informations de publication

Date de publication:
Historique:
received: 26 06 2019
revised: 23 01 2020
accepted: 20 03 2020
pubmed: 6 8 2020
medline: 23 7 2021
entrez: 6 8 2020
Statut: ppublish

Résumé

Tranexamic acid was studied in four different dosage regimens and their efficacy was compared for perioperative blood loss reduction, blood transfusion requirements and deep vein thrombosis (DVT) complication. Two hundred patients undergoing major orthopedic procedures were divided into five groups containing 40 each: placebo, low dose (bolus 10mg.kg The intraoperative blood loss was 440±207.54mL in the placebo group, 412.5±208.21mL in the low dose group, 290±149.6ml in the low dose plus maintenance group, 332.5±162.33mL in the high dose group and 240.7±88.15mL in the high dose maintenance group (p <0.001). The reduction in postoperative blood loss in the drain for the first 24hours was 80±44.44mL in the placebo group, 89.88±44.87mL in the low dose group, 56.7±29.12mL in the low dose plus maintenance group, 77.9±35.74mL in the high dose group and 46.7±19.9mL in the high dose maintenance group (p <0.001). DVT was not encountered in any patient. Tranexamic acid was most effective in reducing surgical blood loss and blood transfusion requirements in a low dose+maintenance group.

Sections du résumé

BACKGROUND BACKGROUND
Tranexamic acid was studied in four different dosage regimens and their efficacy was compared for perioperative blood loss reduction, blood transfusion requirements and deep vein thrombosis (DVT) complication.
METHODS METHODS
Two hundred patients undergoing major orthopedic procedures were divided into five groups containing 40 each: placebo, low dose (bolus 10mg.kg
RESULTS RESULTS
The intraoperative blood loss was 440±207.54mL in the placebo group, 412.5±208.21mL in the low dose group, 290±149.6ml in the low dose plus maintenance group, 332.5±162.33mL in the high dose group and 240.7±88.15mL in the high dose maintenance group (p <0.001). The reduction in postoperative blood loss in the drain for the first 24hours was 80±44.44mL in the placebo group, 89.88±44.87mL in the low dose group, 56.7±29.12mL in the low dose plus maintenance group, 77.9±35.74mL in the high dose group and 46.7±19.9mL in the high dose maintenance group (p <0.001). DVT was not encountered in any patient.
CONCLUSION CONCLUSIONS
Tranexamic acid was most effective in reducing surgical blood loss and blood transfusion requirements in a low dose+maintenance group.

Identifiants

pubmed: 32753113
pii: S0034-7094(20)30346-9
doi: 10.1016/j.bjan.2020.03.013
pmc: PMC9373493
pii:
doi:

Substances chimiques

Antifibrinolytic Agents 0
Tranexamic Acid 6T84R30KC1

Types de publication

Comparative Study Journal Article Randomized Controlled Trial

Langues

por

Sous-ensembles de citation

IM

Pagination

311-317

Informations de copyright

Copyright © 2020 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. All rights reserved.

Références

Orthop Traumatol Surg Res. 2012 Sep;98(5):477-83
pubmed: 22854336
Anesthesiology. 2017 Sep;127(3):413-422
pubmed: 28692467
Interact Cardiovasc Thorac Surg. 2004 Sep;3(3):489-94
pubmed: 17670294
BMJ. 2012 May 17;344:e3054
pubmed: 22611164
J Oral Maxillofac Surg. 2009 Jan;67(1):125-33
pubmed: 19070758
J Surg Res. 2014 Jan;186(1):318-27
pubmed: 24075404
Pharmacotherapy. 2007 Sep;27(9 Pt 2):45S-56S
pubmed: 17723108
Anesthesiology. 2011 Apr;114(4):862-71
pubmed: 21364458
J Cardiothorac Surg. 2009 Jun 18;4:25
pubmed: 19538741
Acta Orthop Traumatol Turc. 2019 Mar;53(2):81-85
pubmed: 30638779
Indian J Anaesth. 2016 Feb;60(2):94-101
pubmed: 27013747
Indian J Anaesth. 2017 Mar;61(3):235-239
pubmed: 28405037
J Bone Joint Surg Am. 2008 Nov;90(11):2399-407
pubmed: 18978408
Clin Orthop Relat Res. 2012 Sep;470(9):2605-12
pubmed: 22419350
Anaesth Intensive Care. 2003 Oct;31(5):529-37
pubmed: 14601276

Auteurs

Ravi Saravanan (R)

SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India.

Rajagopalan Venkatraman (R)

SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India. Electronic address: drvenkat94@gmail.com.

Krishnamoorthy Karthik (K)

SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India.

Anand Pushparani (A)

SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH